The mitochondrial ATP-sensitive potassium channel blocker 5-hydroxydecanoate inhibits toxicity of 6-hydroxydopamine on dopaminergic neurons

Neurotox Res. 2009 Jan;15(1):82-95. doi: 10.1007/s12640-009-9010-8. Epub 2009 Feb 24.

Abstract

The neurotoxin 6-hydroxydopamine is commonly used in models of Parkinson's disease, and a potential factor in the pathogenesis of the disease. However, the mechanisms responsible for 6-hydroxydopamine-induced dopaminergic degeneration have not been totally clarified. Reactive oxygen species (ROS) derived from 6-OHDA uptake and intraneuronal autooxidation, extracellular 6-OHDA autooxidation, and microglial activation have been involved. The mitochondrial implication is controversial. Mitochondrial ATP-sensitive K (mitoK(ATP)) channels may provide a convergent target that could integrate these different mechanisms. We observed that in primary mesencephalic cultures and neuron-enriched cultures, treatment with the mitoK(ATP) channel blocker 5-hydroxydecanoate, inhibits the dopaminergic degeneration induced by low doses of 6-OHDA. Furthermore, 5-hydroxydecanoate blocks the 6-OHDA-induced decrease in mitochondrial inner membrane potential and inhibits 6-OHDA-induced generation of superoxide-derived ROS in dopaminergic neurons. The results suggest that low doses of 6-OHDA may generate low levels of ROS through several mechanisms, which may be insufficient to induce neuron death. However, they could act as a trigger to activate mitoK(ATP) channels, thereby enhancing ROS production and the subsequent dopaminergic degeneration. Furthermore, the present study provides additional data for considering mitoK(ATP) channels as a potential target for neuroprotection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic Agents / toxicity*
  • Analysis of Variance
  • Animals
  • Antihypertensive Agents / pharmacology
  • Benzimidazoles / metabolism
  • Carbocyanines / metabolism
  • Cell Count / methods
  • Cells, Cultured
  • Decanoic Acids / pharmacology*
  • Diazoxide / pharmacology
  • Dopamine / metabolism*
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Embryo, Mammalian
  • Ethidium / analogs & derivatives
  • Glyburide / pharmacology
  • Hydroxy Acids / pharmacology*
  • Membrane Potential, Mitochondrial / drug effects
  • Mesencephalon / cytology
  • Neurons / drug effects*
  • Oxidopamine / toxicity*
  • Potassium Channel Blockers / pharmacology*
  • Potassium Channels / metabolism
  • Rats
  • Reactive Oxygen Species / metabolism
  • Rhodamines / metabolism
  • Time Factors
  • Tritium / metabolism
  • Tyrosine 3-Monooxygenase / metabolism

Substances

  • (((4-chloromethyl)benzoyl)amino)-tetramethylrhodamine
  • Adrenergic Agents
  • Antihypertensive Agents
  • Benzimidazoles
  • Carbocyanines
  • Decanoic Acids
  • Hydroxy Acids
  • Potassium Channel Blockers
  • Potassium Channels
  • Reactive Oxygen Species
  • Rhodamines
  • mitochondrial K(ATP) channel
  • Tritium
  • dihydroethidium
  • 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine
  • 5-hydroxydecanoic acid
  • Oxidopamine
  • Tyrosine 3-Monooxygenase
  • Ethidium
  • Diazoxide
  • Glyburide
  • Dopamine